Puma Biotechnology Priced Like Takeover Target: Real M&A

Puma Biotechnology Inc.’s surging valuation is stoking optimism its chief executive officer will succeed in selling his second straight drug developer to a major pharmaceutical company.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.